In prostate cancer, EMP has been linked to castration resistance, alterations in androgen signalling and PSA expression (Nakazawa and Kyprianou, 2017), in addition to other manifestations of increased aggressiveness such as therapy resistance, migration, invasion and anoikis resistance (Micalizzi et al., 2017). Here, KLK3 is linked to Familial prostate cancer.